(Q38872459)

7 September 2017

title

Cutaneous leishmaniasis: therapeutic strategies and future directions (English)

1 reference

7 September 2017

main subject

cutaneous leishmaniasis

1 reference

Mahreen Ameen

1

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Pharmacotherapy

7 September 2017

published in

1 reference

7 September 2017

volume

8

1 reference

7 September 2017

issue

16

1 reference

7 September 2017

page(s)

2689-2699

1 reference

Leishmaniasis: current situation and new perspectives

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

The psychological impact of cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

T-cell and cytokine responses in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Leishmania major LACK antigen is required for efficient vertebrate parasitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Advances in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Mucosal leishmaniasis ("espundia" Escomel, 1911).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Treatment of recurrent cutaneous Leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Recent advances in vaccines for leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

The genome of the kinetoplastid parasite, Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Role of HLA class II alleles in susceptibility to and protection from localized cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

A policy for leishmaniasis with respect to the prevention and control of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

From genome to vaccines for leishmaniasis: Screening 100 novel vaccine candidates against murine Leishmania major infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2689

10.1517/14656566.8.16.2689

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference